This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

8 Health Care Buys Ahead of Earnings

2. Covance (CVD) is a drug development services company for the pharmaceutical, biotechnology and medical device industries. It also provides laboratory-testing services to the chemical, agrochemical and food industries. Covance will announce third-quarter results on Nov. 2.

For the third quarter of 2011, analysts polled by Bloomberg expect net income of $43.21 million on sales of $526.8 million, compared to a net loss of $32.64 million recorded on $513.3 million sales for the same period in 2010. Earnings per share are forecast at 71 cents for the quarter, a 41% increase from 50 cents in 2010 third quarter.

Gross margin is expected at 31.24%, compared to 27.14% in the earlier-year period. Return on equity is seen increasing to 10.75% from 5.67% for the same period, while return on assets is seen rising to 8.10% from $4.13% earlier.

Of the 20 analysts covering the stock, 55% recommend a buy and the rest suggest a hold. There are no sell ratings on the stock. On average, analysts polled by Bloomberg expect the stock to gain almost 22.6% to $64.39 from current levels over the next 12 months.
7 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WPI $85.73 0.00%
CVD $106.42 0.00%
DVA $74.32 0.00%
HSIC $156.63 0.00%
JAZZ $149.42 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs